Recently added articles from BIOTECH Patent News:
Breckenridge Enters Agreement With Helm to Develop Additional ANDA Project.(Brief article)
Mar 01, 2008 ... Breckenridge Pharmaceutical (Boca Raton, FL) entered into an agreement with Helm AG (Hamburg, Germany) to develop and manufacture a generic ANDA product. Under terms of this new agreement, Breckenridge will submit an ANDA to the United States Food and Drug Administration for the product ...
MAQUET Cardiovascular Announces Patent Infringement Complaints Against Terumo.
Mar 01, 2008 ... MAQUET Cardiovascular LLC (Rastatt, Germany) has filed concurrent patent infringement complaints in the United States International Trade Commission and the United States District Court for the District of Northern California against Terumo Corporation and Terumo Cardiovascular Systems ...
Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials.
Mar 01, 2008 ... Monogram Biosciences, Inc., (South San Francisco, CA) entered into an agreement with Progenics Pharmaceuticals, Inc. (Tarrytown, NY) to provide resistance and tropism testing for Progenics' clinical development program of PRO 140, an investigational CCR5 monoclonal antibody being studied ...
Gen-Probe Begins United States Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer.
Mar 01, 2008 ... Gen-Probe Incorporated (San Diego, CA) has begun a pivotal United States clinical trial of its investigational APTIMA assay to detect human papillomavirus (HPV), which causes cervical cancer. "Starting this highly complex, multi-center study was an important goal for Gen-Probe in early ...
MediPurpose Supports Diabetes Research Effort.
Mar 01, 2008 ... MediPurpose (Norcross, GA), the manufacturer of the SurgiLance safety lancet, has made a donation of $1,000 to the Juvenile Diabetes Research Foundation (JDRF) to support ongoing research efforts. MediPurpose made the recent gift in celebration of the sale of its 500 millionth safety ...
Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program.
Mar 01, 2008 ... Monogram Biosciences, Inc. (South San Francisco, CA) company researchers have co-authored with collaborators from Maxygen, Inc. (Redwood City, CA) and Aldevron LLC several important abstracts presented during the Keystone HIV Vaccines: Progress and Prospects Symposium in Banff, Alberta. ...
Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept Patent Infringement Lawsuit Against Teva Pharmaceuticals.
Mar 01, 2008 ... Eisai Co., Ltd. (Tokyo, Japan) and its United States subsidiary Eisai Inc. (Woodcliff Lake, NJ) announced that the United States District Court for the District of New Jersey has ruled in Eisai's favor with respect to Eisai's motion for a preliminary injunction in its patent infringement ...
Neptune Technologies Patent Granted for Novel Phospholipids in Multiple Diseases and Pharmaceutical Applications.
Mar 01, 2008 ... Neptune Technologies & Bioressources Inc. (Laval, Canada) said the European Patent Office granted on May 31st 2007 Neptune's composition of matter patent entitled, "Natural Marine Source Phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications" (EP01417211B1) ...
FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimer's Disease.
Mar 01, 2008 ... FluoroPharma Inc. (Boston, MA) has entered into a licensing agreement with Massachusetts General Hospital (MGH) for the development and commercialization of agents for diagnosis and treatment of Alzheimer's disease (AD). The licensed technologies, which were co-developed by FluoroPharma ...
Epeius Biotechnologies Awarded United States Patent for Targeted Injectable Gene Delivery In Vivo.
Mar 01, 2008 ... Epeius Biotechnologies Corporation (San Marino, CA) announced the issue of United States Patent 7,347,998 for Targeted Gene Delivery in vivo. This patent provides additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company's ...
United States Patent and Trademark Office Confirms Validity of Osteotech's United States Patent 5,676,146.
Mar 01, 2008 ... Osteotech, Inc. (Eatontown, NJ), a leader in the emerging field of biologic solutions for regenerative medicine, announced that the United States Patent and Trademark Office has confirmed the validity of its United States Patent 5,676,146. The '146 patent covers mixtures of a radiolucent ...
Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics' Scientists.
Mar 01, 2008 ... Rosetta Genomics, Ltd. (Rehovot, Israel), announced that the results of a research study, conducted by its scientists and collaborators and describing the use of microRNAs in accurately identifying tumor origin, have been published in Nature Biotechnology. . The study findings demonstrate ...
UM Scientists Find Key to Low-Cost Ethanol in Chesapeake Bay.
Mar 01, 2008 ... The secret to making an inexpensive substitute to gasoline may come from a bacterium found eating marsh grass in the Chesapeake Bay. A chance discovery not detected in the Bay since, the bacterium, called Saccharophagus degradans, can create a mixture of enzymes --- through a ...
Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts.
Mar 01, 2008 ... Monogram Biosciences, Inc. (South San francisco, CA) has signed an agreement with AVEXA Limited (Melbourne, Australia) to be the exclusive provider of HIV resistance and tropism testing technology in support of Avexa's drug discovery and development programs. Avexa plans to use ...
Consumer Groups Will Continue to Press Stem Cell Patent Challenge.
Mar 01, 2008 ... Two consumer groups said that they will continue their challenge of three overreaching patents on human stem cells held by the Wisconsin Alumni Research Foundation (Madison, WI) despite a non-final decision by Patent Office allowing three amended claims in one of the disputed patents. The ...
Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds.
Mar 01, 2008 ... Lixte Biotechnology Holdings, Inc. (East Setauket, NY) and its collaborator, the Surgical Neurology Branch (SNB), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), reported that its lead compound LB-1, one of a patent-pending proprietary ...
StemCyte Expands Support of World Renowned Spinal Cord Injury Researcher Through Agreement with Rutgers.
Mar 01, 2008 ... StemCyte, Inc. (Arcadia, CA) and Rutgers University (Piscataway, NJ) have entered into a research and licensing agreement for a spinal cord injury therapy being developed by Wise Young, M.D., Ph.D., that uses StemCyte's proprietary human umbilical cord blood (UCB) stem cells in conjunction ...
Caliper and AntiCancer Announce Cross-Licensing of Fluorescent Protein Imaging Intellectual Property and Settlement of Litigation.
Mar 01, 2008 ... Caliper Life Sciences (Hopkinton, MA) and AntiCancer, Inc. (San Diego, CA) have entered into an agreement to establish a cross-licensing relationship and end all outstanding patent litigation between the two companies. Under the new cross-licensing arrangement, Caliper acquires the right ...
Ceres obtains United States patent.
Mar 01, 2008 ... Ceres, Inc. (Thousand Oaks, CA) has patented DNA molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The DNA molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an UTR or as a 3' ...
United States Department of Health and Human Services obtains United States patent.
Mar 01, 2008 ... United States Department of Health and Human Services (Washington, DC) has patented recombinant immunotoxin fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell ...